查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712516

全球子宮肌瘤治療市場 - 2025-2033

Global Uterine Fibroids Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年全球子宮肌瘤治療市場規模達15.8億美元，預計到2033年將達到35.7億美元，在2025-2033年預測期內的複合年成長率為9.5%。

子宮肌瘤（也稱為平滑肌瘤）是由子宮壁內或子宮壁上形成的肌肉和組織構成的生長物。這些腫瘤通常是良性的，是女性最常見的非癌性腫瘤。子宮肌瘤可引起多種症狀，如疼痛和大量不規則陰道出血。有時，患者沒有任何症狀並且不知道自己患有子宮肌瘤。子宮肌瘤的治療通常取決於症狀的嚴重程度。

子宮肌瘤可以作為單一結節（一次生長）或成簇生長。肌瘤簇的大小範圍為直徑 1 毫米至 20 公分（8 英吋）以上，甚至更大。相較之下，子宮肌瘤可以小到像種子一樣，也可以大到像西瓜一樣。這些生長物可以在子宮壁內、子宮主腔或子宮外表面生長。

市場動態：

駕駛員和約束裝置

治療方案的不斷進步極大地推動了子宮肌瘤治療市場的成長。

治療方案的進步是子宮肌瘤市場成長的主要驅動力之一。這些創新為傳統治療提供了更安全、更有效、微創的替代方法，為患者帶來了許多好處，包括縮短恢復時間、降低併發症發生率和改善治療效果。 Myfembree 和 Yselty 等新藥已獲批准透過降低導致子宮肌瘤生長的荷爾蒙水平來治療子宮肌瘤。這些口服藥物提供了一種非侵入性的手術替代方法。

例如，2022年8月，Myovant Sciences和輝瑞公司宣布，美國食品藥品監督管理局（FDA）批准MYFEMBREE（relugolix 40毫克、雌二醇1毫克、醋酸炔諾酮0.5毫克）作為一粒藥、每日一次的療法，用於治療絕經前女性子宮內膜異位症相關的時間中度疼痛相關的重度時間。 MYFEMBREE 也被批准用於治療停經前婦女子宮肌瘤引起的月經過多。

此外，2022 年 6 月，歐盟委員會 (EC) 授予口服 GnRH 拮抗劑 Yselty (linzagolix) 的上市許可，用於治療育齡成年女性（18 歲以上）的中度至重度子宮肌瘤 (UF) 症狀。

認知不足和診斷延遲阻礙了市場成長

認知不足和診斷延遲是阻礙子宮肌瘤治療市場成長的重要因素。許多女性並不了解這種疾病、其症狀以及可用的治療方法，這常常導致診斷和治療處於晚期。這給市場成長帶來了障礙。

許多女性沒有意識到子宮肌瘤的症狀，例如月經量大、骨盆腔疼痛和頻尿。缺乏認知會導致診斷較晚，通常是在肌瘤變大或治療變得更加複雜時。例如，根據美國婦產科醫師學會的研究表明，多達 60% 的子宮肌瘤女性在出現嚴重症狀之前並不知道自己患有子宮肌瘤。

當診斷出子宮肌瘤時，許多女性可能需要更具侵入性或更複雜的治療，例如子宮切除術，如果早期干預，這些治療是可以避免的。如果女性沒有及時就醫，她們就會錯過子宮動脈栓塞術（UAE）或肌瘤切除術等早期治療的機會，而這些治療可能侵入性較小，且更有效地保護生育能力和整體健康。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按類型分類的程式碼片段
  • 治療片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 治療方案不斷進步
      • 荷爾蒙療法的發展
    • 限制
      • 認知有限，診斷延遲
      • 與治療相關的副作用
    • 機會
      • 專注於保留生育能力的治療
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大行銷品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第5章：子宮肌瘤治療市場（按類型）

  • 壁內肌瘤
  • 黏膜下肌瘤
  • 漿膜下肌瘤
  • 帶蒂子宮肌瘤

第6章：子宮肌瘤治療市場（依治療方法）

  • 荷爾蒙療法
    • 醋酸亮丙瑞林
    • 雌二醇
    • 醋酸炔諾酮
    • 其他
  • 促性腺激素釋放激素（GnRH）拮抗劑
    • 惡拉戈利克斯
    • 瑞盧戈利克斯
    • 林札戈利克斯
  • GnRH激動劑
    • 那法瑞林
    • 布舍瑞林
    • 曲普瑞林
    • 其他
  • 黃體素
    • 醋酸甲羥孕酮
    • 醋酸甲地孕酮
  • 選擇性孕酮受體調節劑（SPRM）
    • 米非司酮
    • 烏利司他
    • 特拉司酮
    • 奧那司酮
    • 其他
  • 手術治療
    • 肌瘤切除術
    • 子宮切除術
    • 子宮肌瘤栓塞術
    • 射頻消融
    • 子宮內膜消融術

第7章：子宮肌瘤治療市場，依區域市場分析與成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第8章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第9章：公司簡介

  • AbbVie Inc.
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Pfizer Inc.
  • AstraZeneca
  • Kissei Pharmaceutical Co., Ltd.
  • Theramex

第10章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 11 章：附錄

簡介目錄
Product Code: PH8

The global uterine fibroids treatment market size reached US$ 1.58 billion in 2024 and is expected to reach US$ 3.57 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Uterine fibroids (also called leiomyomas) are growths made of muscle and tissue that form in or on the wall of the uterus. These growths are usually benign and are the most common noncancerous tumors in females. Uterine fibroids can cause a variety of symptoms like pain and heavy, irregular vaginal bleeding. Sometimes, a person has no symptoms and is unaware they have fibroids. Treatment for fibroids typically depends on the severity of the symptoms.

Fibroids can grow as a single nodule (one growth) or in a cluster. Clusters of fibroids can range in size from 1 millimeter to more than 20 centimeters (8 inches) in diameter or even larger. For comparison, fibroids can be as small as a seed or as large as a watermelon. These growths can develop within the wall of the uterus, inside the main cavity of the uterus, or on the outer surface of the uterus.

Market Dynamics: Drivers & Restraints

Rising advancements in treatment options are significantly driving the uterine fibroids treatment market growth.

Advancements in treatment options are one of the key drivers of growth in the uterine fibroids market. These innovations offer safer, more effective, and minimally invasive alternatives to traditional treatments, providing numerous benefits for patients, including reduced recovery time, lower complication rates, and better outcomes. New drugs like Myfembree and Yselty have been approved to treat fibroids by reducing the hormone levels that contribute to fibroid growth. These oral medications provide a non-invasive alternative to surgery.

For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. MYFEMBREE is also approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Additionally, in June 2022, the European Commission (EC) granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Limited awareness and delayed diagnosis hamper the market growth

Limited awareness and delayed diagnosis are significant factors that hamper the growth of the uterine fibroids treatment market. Many women are unaware of the condition, its symptoms, and available treatments, which often leads to late-stage diagnosis and treatment. This creates barriers to market growth.

Many women do not recognize the symptoms of uterine fibroids, such as heavy menstrual bleeding, pelvic pain, and frequent urination. This lack of awareness results in late diagnosis, often when the fibroids have grown larger or become more complicated to treat. For instance, according to the American College of Obstetricians and Gynecologists, studies suggest that up to 60% of women with uterine fibroids are unaware that they have them until they experience severe symptoms.

By the time fibroids are diagnosed, many women may require more invasive or complex treatments, such as a hysterectomy, which could have been avoided with earlier intervention. When women do not seek medical advice on time, they miss the opportunity for early-stage treatments like uterine artery embolization (UAE) or myomectomy, which could be less invasive and more effective in preserving fertility and overall health.

Segment Analysis

The global uterine fibroids treatment market is segmented based on type, treatment, and region.

Treatment:

The surgical treatment segment is expected to dominate the uterine fibroids treatment market with the highest market share.

Surgical treatment remains an effective treatment for uterine fibroids, primarily due to its high efficacy in completely removing fibroids, providing long-term relief from symptoms, and widespread availability. The best treatment for uterine fibroids depends on individual factors, but options range from medication to surgery, with myomectomy (surgical removal of fibroids) being a common choice for those wanting to preserve their uterus, and hysterectomy (removal of the uterus) for those who don't want to get pregnant in the future.

The only permanent solution for uterine fibroids, that it eliminates the possibility of fibroid recurrence. Recommended for women experiencing severe symptoms (e.g., heavy menstrual bleeding, chronic pelvic pain) who do not plan to conceive. For instance, the National Uterine Fibroids Foundation states that a hysterectomy is performed in 30-40% of fibroid cases due to its definitive nature. Over 200,000 hysterectomies are performed annually in the U.S. due to fibroids, making it one of the most common surgical procedures among women.

Geographical Analysis

North America is expected to hold a significant position in the global uterine fibroids treatment market with the highest market share

Uterine fibroids affect 60-80% of women of reproductive age, and the condition is particularly prevalent among African American women, with studies showing that African American women are 2-3 times more likely to develop fibroids compared to Caucasian women. For instance, according to the Centers for Disease Control and Prevention (CDC), uterine fibroids are one of the most common reasons for hysterectomies in the United States, with about 200,000 surgeries performed annually for fibroids. In the United States, nearly 1 in 5 women are affected by uterine fibroids during their lifetime, driving high demand for treatment options.

North America benefits from some of the best healthcare facilities in the world, including specialized centers for gynecology and women's health, which are equipped with state-of-the-art medical technologies for diagnosing and treating uterine fibroids. For instance, the Cleveland Clinic, Johns Hopkins Medicine, and other prominent hospitals offer minimally invasive surgeries like robotic-assisted myomectomy and MRI-guided Focused Ultrasound (MRgFUSl), positioning the region at the forefront of fibroid treatment innovation.

There has been a growing focus on women's reproductive health in North America, resulting in increased awareness about uterine fibroids and their associated symptoms, including heavy bleeding, pelvic pain, and infertility. This has led to more women seeking medical care and treatment options. For instance, in 2021, the Fibroid Foundation in the U.S. conducted awareness campaigns that helped highlight the impacts of uterine fibroids, raising awareness among women and encouraging early diagnosis and treatment.

Competitive Landscape

Top companies in the uterine fibroids treatment market include AbbVie Inc., Pfizer Inc., AstraZeneca, Kissei Pharmaceutical Co., Ltd., and Theramex, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global uterine fibroids treatment market report delivers a detailed analysis with 39 key tables, more than 41 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Treatment
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Treatment Options
      • 3.1.1.2. Development of Hormonal Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Awareness and Delayed Diagnosis
      • 3.1.2.2. Side Effects Associated with the Treatments
    • 3.1.3. Opportunity
      • 3.1.3.1. Focus on Fertility-Preserving Treatments
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Uterine Fibroids Treatment Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Intramural Fibroids*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Submucosal Fibroids
  • 5.4. Subserosal Fibroids
  • 5.5. Pedunculated Fibroids

6. Uterine Fibroids Treatment Market, By Treatment

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 6.1.2. Market Attractiveness Index, By Treatment
  • 6.2. Hormone Therapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Leuprolide Acetate
    • 6.2.4. Estradiol
    • 6.2.5. Norethindrone Acetate
    • 6.2.6. Others
  • 6.3. Gonadotropin-Releasing Hormone (GnRH) Antagonists
    • 6.3.1. Elagolix
    • 6.3.2. Relugolix
    • 6.3.3. Linzagolix
  • 6.4. GnRH Agonists
    • 6.4.1. Nafarelin
    • 6.4.2. Buserelin
    • 6.4.3. Triptorelin
    • 6.4.4. Others
  • 6.5. Progestins
    • 6.5.1. Medroxyprogesterone Acetate
    • 6.5.2. Megestrol Acetate
  • 6.6. Selective Progesterone Receptor Modulators (SPRMs)
    • 6.6.1. Mifepristone
    • 6.6.2. Ulipristal
    • 6.6.3. Telapristone
    • 6.6.4. Onapristone
    • 6.6.5. Others
  • 6.7. Surgical Treatment
    • 6.7.1. Myomectomy
    • 6.7.2. Hysterectomy
    • 6.7.3. Uterine Fibroid Embolization
    • 6.7.4. Radiofrequency Ablation
    • 6.7.5. Endometrial Ablation

7. Uterine Fibroids Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. UK
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. South America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of South America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. AbbVie Inc.*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Pfizer Inc.
  • 9.3. AstraZeneca
  • 9.4. Kissei Pharmaceutical Co., Ltd.
  • 9.5. Theramex

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us